A DNA vaccine tested in mice reduces accumulation of both types of toxic proteins associated with Alzheimer’s disease, according to research that scientists say may pave the way to a clinical trial.
Machine learning can help healthcare workers predict whether patients may require emergency hospital admission, new study finds
A Mexican cavefish could inspire future heart failure treatments through a delicate interplay between proliferation and scarring.
Pharmacogenetic tests are marketed as an aid to psychiatrists in selecting the antidepressant or antipsychotic medication that will work best in individual patients. But for most patients, these pharmacogenetic tests don’t provide much useful information.
A tailored DNA nanoplatform carries chemotherapeutic drugs and RNA interference toward multidrug-resistant tumors
New research from the University of Pittsburgh implicates the so-called “longevity protein” Klotho, both as culprit and therapeutic target.
Gene discovery could help pave way for development treatment for hearing loss
New technology reveals DNA in neurons is ‘mixed and matched,’ producing thousands of previously unknown gene variations — and identifying a potential near-term treatment for Alzheimer’s disease
Single nucleotide variations could be the key to better identification of tumour subpopulations
One of the big issues with chemotherapy is that most treatment approaches focus on the tumour itself without paying significant attention to the microenvironment surrounding the tumour. A new method seeks to solve that.
Health Education England’s Genomics Education Programme has developed a new film series looking at some often-forgotten specialist roles within the genomics multidisciplinary team in a hospital.
Cancer scientists led by principal investigator Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have combined “liquid biopsy,” epigenetic alterations and machine learning to develop a blood test to detect and classify cancer at its earliest stages.
STAT news have put together a great article assessing the need for health care systems to get on top of the payment issue quickly. Give it a read!
The Novartis CAR-T cell therapy, Kymriah (tisagenlecleucel), will be made available to patients under the age of 25 via the Cancer Drugs Fund.
Consumers can contribute to medical breakthroughs and get rewarded for sharing health and genomic data while maintaining privacy and control.